@article{5e706d47693843ef9ec9b18c4efa7df2,
title = "Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort",
abstract = "Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine practice, to serve as a benchmark analysis for comparison BV-CHP efficacy in routine practice. Methods: Patients aged 16 years or older with sALCL treated in seven UK and Australian centres and from 14 additional centres from the UK Haematological Malignancy Research Network database (n = 214). Treatment allocation was clinician choice and included best supportive care (BSC). Main outcomes were time to treatment failure (TTF) and overall survival (OS). Multivariable analysis for predictors of both TTF and OS was also undertaken. Results: The median age 52 years (range 16–93), 18% ECOG ≥ 3 and 40% of cases were ALK positive. CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) was employed in 152 (71%) of patients and CHOEP (CHOP + etoposide) in 4% of patients. For CHOP-treated patients overall response rate (ORR) was 65% and complete response (CR) 47%. Only 9% of patients underwent autologous stem cell transplant (ASCT). With 57 months median follow-up, 4-year TTF and OS were 41.2% (95% CI 33.1–49.1) and 58.9% (95% CI 50.3–66.5) respectively. Multivariable analysis showed ALK+ status was independently associated with superior TTF (HR 0.36, 95% CI 0.21–0.63) but not OS (0.44, 95% CI 0.18–1.07). Discussion: We present a retrospective analysis with mature follow-up of one of the largest multicentre populations of sALCL available, comparable to similar large retrospective studies. ALK status remains a strong predictor of outcomes. Conclusion: These data serve as a robust benchmark for BV-CHP as the new standard of care for sALCL. Similar real-world evidence with BV-CHP will be desirable to confirm the findings of ECHELON-2.",
keywords = "Adcetris, Autologous stem cell transplantation, Brentuximab vedotin, CHOEP, CHOP",
author = "Nicolas Martinez-Calle and Kirkwood, {Amy A.} and Maxine Lamb and Alex Smith and Jahanzaib Khwaja and Kate Manos and Caroline Shrubsole and Nicola Gray and Katharine Lewis and Ann Tivey and Bishton, {Mark J.} and Eliza Hawkes and Ahearne, {Matthew J.} and Wendy Osborne and Collins, {Graham P.} and Timothy Illidge and Linton, {Kim M.} and Kate Cwynarski and Cathy Burton and Fox, {Christopher P.}",
note = "Funding Information: Nicolas Martinez-Calle: Conference travel and accommodation support from Takeda. Kate Manos: Janssen, Honoraria; Novo Nordisk Pharmaceuticals, Travel. Mark Bishton: Takeda, travel support, Research Funding; Janssen, Advisory committees; Celgene, Research Funding; AbbVie, Research Funding; Celltrion, Advisory committees, travel support; Roche, travel support, Research Funding. Eliza Hawkes: Bristol-Myers Squibb, Research Funding, Speakers Bureau; Celgene, advisory committees, research Funding; Mundi pharma, research Funding; Merck Sharp & Dohme, advisory committees; Roche/Genentech, advisory committees, travel expenses, speakers Bureau; Roche, research Funding; AstraZeneca, Research Funding; Merck KgA, Research Funding; Janssen-Cilag, advisory committees, Research Funding, speakers Bureau; Gilead, advisory committees, research Funding; Takeda, Speakers Bureau. Matthew Ahearne: Takeda, Consultancy and honoraria. Wendy Osborne: Gilead, Consultancy; Pfizer, honoraria, speakers Bureau; Takeda, consultancy, travel, Speakers Bureau; Novartis, travel; Servier, consultancy; MSD, consultancy; Roche, consultancy, Honoraria, travel, speakers Bureau. Christopher Fox: Remunerated consultant/advisor for Takeda. Graham Collins: COI: Honoraria for advisory and speaker work from Takeda. Kate Cwynarski: Takeda: Consulting/Advisory Role and Conferences/Travel support. Kim Linton: Beigene, advisory committees; Celgene, advisory committees; Roche, Consultancy; Gilead, advisory committees; Karyopharm, advisory committees; Takeda, Honoraria; Janssen, Travel expenses; Celgene, Travel expenses. Amy Kirkwood, Maxine Lamb, Alexandra Smith, Nicola Gray, Katharine Lewis, Jahanzaib Khwaja, Ann Tivey and Cathy Burton: None to declare. Graham Collins acknowledges support from the Oxford NIHR Biomedical Research Centre and CRUK Experimental Cancer Medicines Centre. Haematological Malignancy Research Network is funded by Cancer Research UK, grant numbers 29685; and Blood Cancer UK, grant number 15037. Publisher Copyright: {\textcopyright} 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jul,
doi = "10.1007/s12325-021-01764-0",
language = "English",
volume = "38",
pages = "3789–3802",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer - Adis",
number = "7",
}